Hyperandrogenism

10

Review clinical trials related to Hyperandrogenism. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)

This pilot randomized controlled study will plan to enroll 36 adolescent females with Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) to evaluate the effectiveness and feasibility of a tailored dietary intervention which will be termed "Beef+", that will emphasize the incorporation of unprocessed, lean beef (\<10% fat) as part of a healthy meal plan to improve glycemic control, diet quality, and health-related quality of life

Participants needed: 36
Trial details
Age: 11-17Biological sex: FemaleType: InterventionalSponsor: Texas A&M UniversityUpdated: Aug 21, 2026Locations: 1
Eligibility criteria

Female Adolescent [+5]

Medications affecting glucoregulation, metabolic health, and/or appetite (e.g.,... [+7]

Status: Not yet recruiting

Biomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS)

This single-center, prospective, observational, cross-sectional mechanistic pilot study will evaluate whether polycystic ovary syndrome (PCOS) contributes to hepatic steatosis in adolescent girls independently of adiposity. A total of 150 girls aged 10-18 years will be enrolled into three groups of 50: girls with PCOS and obesity, age- and body mass index-matched girls with obesity but without PCOS, and healthy normal-weight girls. Each participant will undergo a single evaluation comprising anthropometry, clinical and biochemical phenotyping, transient elastography with controlled attenuation parameter and two-dimensional shear wave elastography, and a single venous blood sample. An extended biomarker panel will be measured by enzyme-linked immunosorbent assay (Fetuin-A, fibroblast growth factor 21, adiponectin, visfatin, cytokeratin-18 M30 and M65, soluble CD163, growth differentiation factor 15, 11-ketotestosterone, and 11beta-hydroxyandrostenedione), together with liquid chromatography-tandem mass spectrometry measurement of testosterone and sex hormone-binding globulin, and genotyping of PNPLA3 rs738409 and HSD17B13 rs72613567. The primary objective is to compare hepatic steatosis and the hepatokine/adipokine profile between the PCOS with obesity group and the adiposity-matched obesity control group, adjusting for body mass index z-score, insulin resistance, and free androgen index. No therapeutic intervention is assigned by the study protocol.

Participants needed: 150
Trial details
Age: 10-18Biological sex: FemaleType: ObservationalSponsor: Kayseri City HospitalUpdated: Jul 30, 2026Locations: 1
Eligibility criteria

Female, aged 10 to 18 years, with written informed consent from a parent or lega... [+3]

Known acute or chronic liver disease (including viral, autoimmune, or Wilson dis... [+5]

Status: Not yet recruiting

Combined Use of Machine Learning and Metabolomics to Improve the Diagnosis and Management of Hyperandrogenism

Hyperandrogenism is a common reason for consultation, the causes of which can range from common conditions (PCOS) to rarer conditions with major genetic implications (NC21OHD). It is characterized by elevated levels of circulating androgens, mainly testosterone. This excess of androgens usually manifests clinically as increased male-pattern hair growth and, less specifically, acne and alopecia. Its prevalence is estimated at between 6 and 12% in women of reproductive age, and its incidence is increasing. It is also responsible for infertility. As a reminder, infertility is a major public health issue and affects more and more couples around the world. The investigators therefore wish to develop innovative tools to improve the diagnosis and management of hyperandrogenism

Participants needed: 800
Trial details
Age: 16-45Biological sex: FemaleType: ObservationalSponsor: Assistance Publique - Hôpitaux de ParisUpdated: Dec 4, 2025
Eligibility criteria

Patients of childbearing age (16 to 45 years old) [+3]

Pregnancy [+1]

Status: Recruiting

Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS

The aim of the present study is to investigate a) the presence of subclinical markers of vascular, myocardial and endothelial function in women with PCOS b) the acute alterations in these markers during the oral glucose tolerance test (OGTT) c) the impact of potential treatment interventions in these markers.

Participants needed: 120
Trial details
Age: 18-45Biological sex: FemaleType: ObservationalSponsor: Attikon HospitalUpdated: Nov 19, 2025Locations: 1
Eligibility criteria

Age > 16 years old [+5]

Disorders with clinical presentation similar to PCOS: thyroid disease, hyperprol... [+6]

Status: Recruiting

Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?

The purpose of this study is to determine if, in mid- to late pubertal girls with hyperandrogenism (HA), androgen-receptor blockade (spironolactone) alone normalizes sleep-wake luteinizing hormone (LH) pulse frequency (primary endpoint) and overall LH and follicle-stimulating hormone secretion (secondary endpoints).

Participants needed: 32
Trial details
Phase: Early Phase 1Age: 10-17Biological sex: FemaleType: InterventionalSponsor: University of VirginiaUpdated: Aug 5, 2025Locations: 1
Eligibility criteria

Mid- to late pubertal adolescent girls as signified by either (a) post-menarchea... [+3]

Inability/incapacity to provide informed consent [+25]

Status: Recruiting

Hyperandrogenemia and Altered Day-night LH Pulse Patterns

The purpose of this study is to determine if, in mid- to late pubertal girls with hyperandrogenism, androgen-receptor blockade (spironolactone) improves the ability of progesterone to acutely reduce waking luteinizing hormone pulse frequency (primary endpoint).

Participants needed: 32
Trial details
Phase: Early Phase 1Age: 10-17Biological sex: FemaleType: InterventionalSponsor: University of VirginiaUpdated: Aug 5, 2025Locations: 1
Eligibility criteria

Mid- to late pubertal adolescent girl (at least Tanner breast stage 3, but no mo... [+4]

Inability/incapacity to provide informed consent [+24]

Status: Recruiting

Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

The purpose of this study is two-fold. (1) We will determine if in mid- to late pubertal girls without hyperandrogenism (HA), progesterone (P4) acutely reduces waking luteinizing hormone (LH) frequency to a greater extent than sleep-associated LH frequency. (2) We will determine if in mid- to late pubertal girls with HA, P4 will acutely suppress waking LH frequency to a lesser degree than it does in girls without HA.

Participants needed: 36
Trial details
Phase: Early Phase 1Age: 10-17Biological sex: FemaleType: InterventionalSponsor: University of VirginiaUpdated: Aug 5, 2025Locations: 1
Eligibility criteria

Mid- to late pubertal adolescent girl (at least Tanner breast stage 3, but no mo... [+5]

Inability/incapacity to provide informed consent [+24]

Status: Recruiting

Acupuncture or Metformin for Insulin Resistance in Women With PCOS

The hypothesis is that acupuncture is equally effective as metformin (both treatments combined with lifestyle management) in improving whole body glucose homeostasis in insulin resistant women with polycystic ovary syndrome (PCOS), and that both are superior to lifestyle management alone. The investigators hypothesize that acupuncture and metformin induce ovulation and improve hyperandrogenism, as well as health related quality of life (HRQoL) and symptoms of anxiety and depression. Although equally effective (acupuncture and metformin), the investigators hypothesize that acupuncture is associated with less negative side-effects. The investigators also hypothesize that these treatments have the potential to restore epigenetic and molecular alterations in target tissues (endometrial-, adipose-, and skeletal muscle tissue) and thus have the potential to prevent the development of type 2 diabetes (T2D).

Participants needed: 303
Trial details
Phase: Phase 2Age: 18-40Biological sex: FemaleType: InterventionalSponsor: Karolinska InstitutetUpdated: Oct 9, 2024Locations: 2
Eligibility criteria

Age 18 to 40 years [+3]

Age >40 [+11]

Status: Recruiting

FEmale Metabolic Risk and Androgens: an Irish Longitudinal (FEMAIL) Study

Androgen excess is the cardinal biochemical feature of polycystic ovary syndrome (PCOS), a lifelong metabolic disorder affecting 10% of women. Serum testosterone correlates with insulin resistance in women, however, there is an urgent need to improve our understanding of the association between androgens and the risk of type 2 diabetes. Recently, a new subclass of androgenic steroids known as 11-oxygenated androgens has been identified. Utilising highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) techniques, our group has recently demonstrated that 11-oxygenated steroids are the predominant androgens in both health controls and women with PCOS, and that these correlate closely with markers of insulin resistance. The bioactive 11-oxygenated androgen 11-ketotestosterone (11KT) binds and activates the androgen receptor with equal affinity to testosterone, yet nothing is known about its impact on metabolism or glucose homeostasis. Intriguingly, unlike testosterone, 11-oxygenated androgens do not decline with age in women, and, therefore, may mediate an increased risk of T2DM in women across their life course. Therefore, this previously ignored androgen class is likely of major importance in female metabolic health, and may represent a novel metabolic risk factor and biomarker. However, 11-oxygenated androgens are not currently measured in routine clinical practice. To date, no population-based or human in vivo physiology studies have examined the association between 11-oxygenated androgens, glucose metabolism and diabetes risk in women, despite the high prevalence of PCOS in the female population. There is emerging evidence, even in women without a confirmed history of PCOS, that the levels of androgens over time correlate with their likelihood of developing metabolic and cardiovascular disease. This has not been studied to date in a prospective manner in healthy women in the background population using long term follow up data.

Participants needed: 500
Trial details
Age: 18+Biological sex: FemaleType: ObservationalSponsor: Royal College of Surgeons, IrelandUpdated: May 2, 2024Locations: 1
Eligibility criteria

Age 18 years or above [+1]

Pregnancy or breastfeeding at the time of planned recruitment [+6]

Status: Recruiting

Offspring Born to Mothers With Polycystic Ovary Syndrome in Guangzhou Cohort Study

The Offspring Born to Mothers with Polycystic Ovary Syndrome in Guangzhou Cohort study (PCOS-BIG) was established to investigate the short- and long-term effects of intrauterine exposure to maternal PCOS on the health of offspring in Guangzhou, China. Data are collected regarding maternal PCOS subtypes, nursing, diet and education as well as health outcomes in their later life. Biological samples including blood and tissue samples are also collected from participants.

Participants needed: 2,000
Trial details
Age: Up to 18Biological sex: AllType: ObservationalSponsor: Guangzhou Women and Children's Medical CenterUpdated: Feb 26, 2024Locations: 1
Eligibility criteria

Offspring born to women diagnosed with PCOS [+2]

None